A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC
SOCRATES HCC will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour.
Primary Sponsor
Collaborating Groups
Australasian Gastro-Intestinal Trials Group (AGITG), Abdominal Radiology Group of Australia and New Zealand (ARGANZ) & Gastrointestinal Society of Australia (GESA)
Participating Centres
Accrual Target
218
Current Accrual
Trial Chairperson
Prof Alan Wigg, Flinders Medical Centre, SA, Australia
A/Prof David Pryor, Princess Alexandra Hospital, QLD, Australia
Trial Contact
SOCRATES_HCC@trog.com.au
Clinical Trial Registration
Related Post
Diversity, equity and inclusion at heart of TROG work
15 October 2024: TROG Cancer Research has made a
A plan for the future of cancer research
12 September 2024: TROG Cancer Research has outlined how
